Novartis Ag

Novartis Pharmaceuticals Corporation

Novartis Tiergesundheit Ag

Novartis Pharma Gmbh

Bernhard Riss

David Hook

Erhard Bappert

Matthias Napp

Gottfried Sedelmeier

Liladhar Murlidhar Waykole

Thomas Ruch

Bernhard Wietfeld

Jianguang Zhou

Lech Andrzej Ciszewski

Yunzhong Li

Markus Bänziger

Steven Hawker

Mahavir Prashad

Antonio Zanotti-Gerosa

Murat Acemoglu

Ulrich Meier

Yugang Liu

Daniel Kaufmann

Pietro Bollinger

Peter C Hiestand

Jonathan Medlock

Philippe Polleux

Janet Dawson King

Jonathan King

Vincent Schmid

Friedrich Schuerch

Markus Banziger

The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a &#x3b3;-amino-&#x3b4;-biphenyl-&#x3b1;-methylalkanoic acid, or acid ester, backbone, such as N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.

Process for the preparation of intermediates useful for the manufacture NEP inhibitors

The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a -amino- -biphenyl- -methylalkanoic acid, or acid ester, backbone, such as N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.

The present invention relates to pyrrolidin-2-ones according to the formula (1), or salts thereof, wherein R1 is hydrogen or a nitrogen protecting group, methods for their preparation and their use in the preparation of NEP-inhibitors, particularly in the preparation of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.

Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid

The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a &#x3b3;-amino-&#x3b4;-biphenyl-&#x3b1;-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.

Processes

The present invention relates to a method of preparing N-substituted salicylamides or derivatives thereof, and their salts, hydrates and solvates. In particular, the present invention relates to a method of preparing N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) and its corresponding disodium monohydrate.

Manufacture process of organic compounds

The present invention relates to novel aza-thia-benzoazulene derivatives of formula I as defined in the claims, their preparation, the use of these novel compounds for the preparation of pharmaceutical compositions, the use of these novel compounds and compositions for managing arthritis and arthritis-related conditions as well as in the treatment of pain in animals and humans. More particularly, the present invention relates to pharmaceutical, preferably veterinary compositions and methods for reducing inflammation and pain associated with acute inflammation of body parts, particularly joints, due to injury or due to arthritic conditions or other disease conditions.

Organic compounds

The present invention relates to a method of preparing N-substituted salicylamides or derivatives thereof and their derivatives, e.g. their salts. In particular, the present invention relates to a method of preparing (N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) and its corresponding disodium monohydrate.

The invention relates to a process for the manufacture of a compound of formula or a salt, especially a pharmaceutically acceptable salt with a base, thereof or a lactone thereof wherein the elementrepresents &#x2014;CH&#x2014;CH&#x2014; or &#x2014;CH&#x2550;CH&#x2014; and R represents a cyclic residue.

Process for the manufacture of HMG-CoA reductase inhibitors

Growing community of inventors

Huningue, France

Bernhard Riss